iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference
Insight Molecular Diagnostics (Nasdaq: IMDX) has scheduled its second quarter 2025 financial results release for August 11, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) has scheduled its second quarter 2025 financial results release for August 11, 2025, after market close. The company will host a live Zoom webinar at 2:00 PM PT / 5:00 PM ET on the same day to discuss the results, followed by a Q&A session.
Additionally, CEO Josh Riggs and CFO Andrea James will participate in the 10th Annual Needham Virtual MedTech & Diagnostics Conference on August 12, 2025, where they will be available for one-on-one meetings with investors.
Details
News Market Reaction – IMDX
On Aug 5, the first trading day after this news, IMDX closed 5.78% below the previous close.
Data tracked by StockTitan Argus for the Aug 5 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q2 2025 Earnings Webinar.
An archived replay will be available after the call concludes on iMDX’s investor relations website at https://investors.imdxinc.com/.
10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Separately, on August 12th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 10th Annual Needham Virtual MedTech & Diagnostics Conference, taking place from August 11-12, 2025.
Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Needham sales representative.
Event: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Dates: August 12, 2025
Location: Virtual
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.
iMDx™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
dfarrell@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.